Pharmaceutical Continuous Manufacturing Market

Market Overview:

The global pharmaceutical continuous manufacturing market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.6% during 2023-2028.

Pharmaceutical continuous manufacturing refers to an end-to-end medication production approach that enhances the quality and consistency of various novel drugs and vaccines with minimal capital investments. As compared to batch processing, it operates in a continuous flow, is easier to scale, offers greater control to manufacturers and a higher level of automation, and eliminates physical intervention. Apart from this, pharmaceutical continuous manufacturing aids in minimizing the medicine formulation duration, risk of human errors, monitoring the production procedures, and improving the product quality to harmonize with the regulatory guidelines. Consequently, the technique is extensively utilized by pharmaceutical companies and contract manufacturing organizations (CMOs) to develop active pharmaceutical ingredients (API) and medicines. At present, it is available in integrated, semi-continuous, and control types. 

Pharmaceutical Continuous Manufacturing Market Trends:

One of the primary factors currently driving the global pharmaceutical continuous manufacturing market is the increasing demand for effective medicine production systems for composing various effective biologics at a lower cost. This can be further attributed to the rising drug shortages and the growing prevalence of several chronic ailments across the globe. Additionally, the rising health concerns, especially during the coronavirus disease (COVID-19) pandemic outbreak, have prompted pharmaceutical companies to use continuous manufacturing techniques to compose novel vaccines, which is acting as another growth-inducing factor. In line with this, significant technological advancements, such as rapid automation in the pharmaceutical manufacturing methodology and the large-scale integration of artificial intelligence (AI) solutions, are contributing to the market growth. Other factors, such as significant improvements in the pharmaceutical sector, ongoing research and development (R&D) activities, and the escalating awareness about the availability of food and drug administration (FDA) approved medicines, are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmaceutical continuous manufacturing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapeutics type, formulation, application and end user.

Breakup by Therapeutics Type:

• Large Molecules
• Small Molecules
   

Breakup by Formulation:

• Solid Formulation
• Liquid and Semi-solid Formulation
   

Breakup by Application:

• Final Drug Product Manufacturing
• API Manufacturing
   

Breakup by End User:

• Pharmaceutical Companies
• Contract Manufacturing Organizations
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baker Perkins, Coperion GmbH (Hillenbrand Inc.), Eli Lilly and Company, GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Novartis AG, Siemens, SK biotek, Thermo Fisher Scientific Inc. and Viatris Inc.

Report Coverage: